Recombinant human interleukin-11 (rhIL-11, oprelvekin) received FDA approval for the prevention of chemotherapy-induced thrombocytopenia (CIT) in patients with nonmyeloid malignancies [32]. The gene discussed is IL11; the disease is Thrombocytopenia.